The challenge of comorbidity in clinical trials for multiple sclerosis

Neurology

Volumn 86, Issue 15, 2016, Pages 1437-1445

  Marrie, Ruth Ann ^a   Miller, Aaron ^b   Sormani, Maria Pia ^c   Thompson, Alan ^d   Waubant, Emmanuelle ^e   Trojano, Maria ^f   O'Connor, Paul ^g   Reingold, Stephen ^h   Cohen, Jeffrey A ⁱ  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF BARI   (Italy)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h Scientific and Clinical Review Associates LLC   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

AGE; ANXIETY DISORDER; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BLOOD PRESSURE; BODY MASS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MIGRAINE; MULTIPLE SCLEROSIS; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH PRIORITY; SEX DIFFERENCE; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); WAIST HIP RATIO; WORKSHOP; COMPLICATION; CONSENSUS DEVELOPMENT; ETHICS; PROCEDURES;

CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; MULTIPLE SCLEROSIS;

EID: 84964865861     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002471     Document Type: Article

References (52)

1. National Center for Chronic Disease Prevention and Health Promotion. Chronic Diseases: The Power to Prevent, the Call to Control. Hyattsville, MD: Centers for Disease Control; 2009.
2. Caughey G, Vitry A, Gilbert A, Roughead E. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health 2008;8:221.
3. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001;54: 661-674.
4. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009; 7:357-363.
5. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler J 2015;21:263-281.
6. Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 2015;84:350-358.
7. Weinstock-Guttman B, Zivadinov R, Mahfooz N, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011;8:127.
8. Tettey P, Simpson S, Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler J 2014;20: 1737-1744.
9. Warren SA, Turpin KV, Pohar SL, Jones CA, Warren KG. Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care 2009;11:6-16.
10. Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS. Descriptions of barriers to self-care by persons with comorbid chronic diseases. Ann Fam Med 2003;1:15-21.
11. Ani C, Bazargan M, Hindman D, Bell D, Rodriguez M, Baker RS. Comorbid chronic illness and the diagnosis and treatment of depression in safety net primary care settings. J Am Board Fam Med 2009;22:123-135.
12. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516-1520.
13. Rost K, Nutting P, Smith J, Coyne JC, Cooper-Patrick L, Rubenstein L. The role of competing demands in the treatment provided primary care patients with major depression. Arch Fam Med 2000;9:150-154.
14. Nuyen J, Spreeuwenberg PM, Van Dijk L, den Bos GAMV, Groenewegen PP, Schellevis FG. The influence of specific chronic somatic conditions on the care for co-morbid depression in general practice. Psychol Med 2007;38:265-277.
15. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-47.
16. Kalsekar ID, Madhavan SS, Amonkar MM, et al. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis. Clin Ther 2006; 28:306-318.
17. Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int 2011;2011:271321.
18. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-533.
19. Finlayson M, Preissner K, Cho C. Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis. Int J MS Care 2013;15:21-26.
20. Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PLoS One 2012;7:e41601.
21. Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 2011;306:2670-2672.
22. Buck HG, Akbar JA, Zhang SJ, Bettger JA. Measuring comorbidity in cardiovascular research: a systematic review. Nurs Res Pract 2013;2013:563246.
23. The IFNB Multiple Sclerosis Study Group. Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
24. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
25. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
26. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double- blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025.
27. PRISMS Study Group. Randomized double-blind placebo- controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
28. Polman CH, OConnor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
29. Kappos L, Radue EW, OConnor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
30. OConnor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-1303.
31. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral Bg-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
32. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004;62:2058-2064.
33. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:174-179.
34. Patti F, Nicoletti A, Pappalardo A, et al. Frequency and severity of headache is worsened by interferon-b therapy in patients with multiple sclerosis. Acta Neurol Scand 2012; 125:91-95.
35. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 2012; 78:672-680.
36. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 2011;13:217-224.
37. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464-475.
38. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015;350:h2147.
39. Loudon K, Zwarenstein M, Sullivan F, Donnan P, Treweek S. Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose. Trials 2013;14:115.
40. Weiss CO, Varadhan R, Puhan MA, et al. Multimorbidity and evidence generation. J Gen Intern Med 2014;29: 653-660.
41. Wiktorowicz M, Lexchin J, Paterson M, et al. Research Networks Involved in Post-Market Pharmacosurveillance in the United States, United Kingdom, France, New Zealand, Australia, Norway and European Union: Lessons for Canada. Edmonton, Alberta: Patient Safety Institute; 2008.
42. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-1047.
43. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta- 1a in early multiple sclerosis. N Engl J Med 2008;359: 1786-1801.
44. Giovannoni G, Comi G, Cook S, et al. A placebocontrolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-426.
45. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-1707.
46. Stewart S, Carrington MJ, Horowitz JD, et al. Prolonged impact of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort. Int J Cardiol 2014; 174:600-610.
47. Stewart S, Carrington MJ, Marwick T, et al. The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of home- vs. clinicbased management of chronic heart failure patients. Eur J Heart Fail 2011;13:909-916.
48. den Broeder A, van Herwaarden N, van der Maas A, et al. Dose reduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299.
49. van Herwaarden N, van der Maas A, Minten MJM, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 2015; 350:h1389.
50. Watson TM, Ford E, Worthington E, Lincoln NB. Validation of mood measures for people with multiple sclerosis. Int J MS Care 2014;16:105-109.
51. Terrill AL, Hartoonian N, Beier M, Salem R, Alschuler K. The 7-item Generalized Anxiety Disorder Scale as a tool for measuring generalized anxiety in multiple sclerosis. Int J MS Care 2015;17:49-56.
52. Webster R, Hind D, Kaklamanou D, Beever D, Barkham M, Cooper C. The assessment of depression in people with multiple sclerosis: a systematic review of psychometric validation studies. PROSPERO 2014;2014: CRD42014010597.